Clinical trials: COVID-19; Immunity
Genetic Predisposition to Disease
Immunogenetics Predictors With COVID-19
Background: There is a current worldwide outbreak of the novel coronavirus Covid-19 which originated from Wuhan in China and has now spread to 6 continents including 210 countries.
- Trial name
- NCT04390269
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Mansoura University
SARS-CoV-2, COVID-19
Vienna Versus SARS-CoV-2 Virus Study
This study examines the seroprevalence against SARS-CoV-2 in health care workers and patients at the Vienna General Hospital.
- Trial name
- VIVI (NCT04407429)
- Testing
- Laboratory Analyses
- Where
- Austria
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
COVID-19
A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.
This is a study to evaluate the ability of UB-612 vaccine to boost immunity of subjects who previously received two doses of AstraZeneca COVID-19 vaccine (ChAdOx1-S) with an 8-16 week interval between first and second doses.
- Trial name
- NCT05167253
- Testing
- UB-612
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical Inc., Asia
COVID-19; Immunity
Investigating Immune Escape by SARS-CoV-2 Variants
The purpose of this protocol is to investigate the ability of pre-existing immunity by natural infection or vaccination to prevent infections by emerging SARS-CoV-2 variants.
- Trial name
- NCT05171803
- Testing
- No intervention
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of California, Los Angeles
COVID-19, Serology
Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms
Three hundred healthcare workers with mild symptoms for Covid-19 will be followed during three months. Each two weeks, serological tests will be performed. Re-infection will be monitored by saliva-swabs.
- Trial name
- NCT04356586
- Where
- Belgium
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- Sciensano
Vaccine Adverse Reaction, COVID-19
Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.
Background: Scarce information exists in relation to the comparison of seroconversion and adverse events following immunization (AEFI) with different SARS-COV2 vaccines.
- Conditions
- Vaccine Adverse Reaction, COVID-19, Vaccine Reaction
- Trial name
- NCT05228912
- Testing
- COVID-19 Vaccines
- Where
- Mexico
- Volunteers
- 1,870 people, healthy volunteers welcome
- Sponsor
- Hospital Clinica Nova
SARS CoV 2 Infection
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
This is an open-label study examining the safety and tolerability of sotrovimab, administered in two sequential doses as prophylaxis in immunocompromised patients with impaired humoral immunity against SARS-CoV-2.
- Trial name
- NCT05210101
- Testing
- Sotrovimab
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Sophia Koo, M.D.
COVID-19
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
Background: People who get infected with COVID-19 have an unpredictable risk to worsen and die. This makes it hard to decide who can quarantine at home and who should be treated at a hospital.
- Trial name
- NCT04362865
- Where
- 4 sites in United States
- Volunteers
- 679 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19)
COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
The most recently discovered coronavirus (SARS-CoV-2) may cause illness in humans ranging from the common cold to serious illness, also referred to as Coronavirus disease 2019 (COVID-19).
- Trial name
- CV-NCOV-011 (NCT04848467)
- Testing
- SARS-CoV-2 mRNA Vaccine (CVnCoV), Quadrivalent influenza vaccine (QIV)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bayer
COVID-19, Probiotic
A Randomised-controlled Trial of an Oral Microbiome Immunity Formula in Recovered COVID-19 Patients
This study aims to evaluate the effectiveness of an oral microbiome immunity formula in modulating gut microbiota, enhancing immunity and reducing long-term complications and co-morbidities in patients who have recovered from…
- Trial name
- NCT04950803
- Testing
- Microbiome immunity formula
- Where
- Hong Kong
- Volunteers
- 448 people
- Sponsor
- Chinese University of Hong Kong
SARS CoV 2 Infection
Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence
This is a Phase II study with single-blinded safety phase followed by double-blinded randomization, placebo-controlled, of administration of a single dose by two different administration routes (intramuscular route or intranasal…
- Trial name
- NCT05205746
- Testing
- Recombinant NDV Vectored Vaccine for SARS-CoV-2
- Where
- 4 sites in Mexico
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Laboratorio Avi-Mex, S.A. de C.V.
COVID-19
Understanding Adaptive Immune Response After COVID-19 Vaccination Boosters to Improve Vaccination Strategies in Vulnerable Groups.
This is an experimental study without drug and device, non-profit, single-center. The general objective of the project is to study how the adaptive immune response evolves against SARS-CoV-2 with repeated vaccination boosters and…
- Trial name
- COVaxFragile (NCT06300853)
- Testing
- Analisys of cellular response and humoral response to SARS-CoV-2 vaccine booster doses
- Where
- Italy
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Covid19, Thromboembolism
Cellular-Mediated Immunity in COVID-19
In order to prevent reinfection, it is needed to detect the cellular-mediated immune response to the Sars-CoV-2 infection. The first goal of this study will be to detect the cellular-mediated immune response in patients affected…
- Trial name
- DEMETRA (NCT04746521)
- Testing
- Multitest 6 color TBNK and BD Lyotubes, genomicDNA extraction
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Campania Luigi Vanvitelli
COVID - 19
Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers
This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration…
- Trial name
- NCT06831786
- Testing
- Bivalent mRNA SARS-CoV-2 vaccine, Quardrivalent influenza vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Prince of Songkla University
SARS-COV2 Virus
SARS-COV2 Pandemic Serosurvey and Blood Sampling
Background: Respiratory virus outbreaks and pandemics, such as SARS, MERS, and the new SARS-COV2 virus, have major impacts worldwide.
- Trial name
- NCT04334954
- Where
- 3 sites in United States
- Volunteers
- 11,363 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunology, Allergy
Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort
The major role of human genetic factors in the immune response to infections is now well established, particularly for viral infections.
- Conditions
- Immunology, Allergy, Genetic Diseases, Infectious Diseases
- Trial name
- COVIFERON (NCT06762002)
- Testing
- blood sample
- Where
- 9 sites in France
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Humoral Immunity
Humoral Immunity Study After a Booster Dose of Soberana Plus (FINLAY-FR-1A) Vaccine Against COVID-19
To evaluate the dynamics of IgG levels to the SARS-CoV-2 virus after a booster dose of Soberana Plus vaccine.
- Trial name
- NCT05689177
- Testing
- Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)
- Where
- Belarus
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gomel State Medical University
COVID - 19
Retail COVID-19 Study
Despite the availability of vaccines, there remains a need to identify specific immune responses that correlate with protection against SARS-CoV-2 infection.
- Trial name
- NCT06761612
- Testing
- FDA approved mRNA vaccines
- Where
- 20 sites in United States
- Volunteers
- 2,519 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
COVID-19
Evaluating the Immune Response for COVID-19
The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic. The measures in which public health officials quarantine confirmed and isolate symptomatic cases in order to reduce the spread COVID-19 is the common…
- Trial name
- COVIDIMMUNE (NCT04348422)
- Testing
- COVID-19 RT-PCR, COVID-19 Serology, Symptoms questionnare
- Where
- Israel
- Volunteers
- 214 people
- Sponsor
- Assaf-Harofeh Medical Center
COVID-19
Immune Responses to COVID-19 Infection or Vaccination
The overall purpose of this observational cohort study is to characterize COVID-specific immune responses to SARS-CoV-2 exposure or COVID vaccination in a real-world setting.
- Trial name
- NCT05379478
- Testing
- Laboratory assessment of antibody profiles
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- Aditxt, Inc.